CN116930390A - 一种检测头孢噻肟钠他唑巴坦钠中有关物质的二维液相色谱-串联质谱分析方法 - Google Patents
一种检测头孢噻肟钠他唑巴坦钠中有关物质的二维液相色谱-串联质谱分析方法 Download PDFInfo
- Publication number
- CN116930390A CN116930390A CN202210341487.4A CN202210341487A CN116930390A CN 116930390 A CN116930390 A CN 116930390A CN 202210341487 A CN202210341487 A CN 202210341487A CN 116930390 A CN116930390 A CN 116930390A
- Authority
- CN
- China
- Prior art keywords
- mobile phase
- sodium
- mass spectrometry
- dimensional
- liquid chromatography
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 title claims abstract description 17
- 229960002727 cefotaxime sodium Drugs 0.000 title claims abstract description 16
- NDIURPSCHWTXDC-UHFFFAOYSA-N 2-(4,5-dimethoxy-2-nitrophenyl)acetohydrazide Chemical compound COC1=CC(CC(=O)NN)=C([N+]([O-])=O)C=C1OC NDIURPSCHWTXDC-UHFFFAOYSA-N 0.000 title claims abstract description 15
- 229960000373 tazobactam sodium Drugs 0.000 title claims abstract description 15
- 239000000126 substance Substances 0.000 title claims abstract description 13
- 238000004458 analytical method Methods 0.000 title claims abstract description 12
- 238000005109 two-dimensional liquid chromatography tandem mass spectrometry Methods 0.000 title claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 23
- 238000004949 mass spectrometry Methods 0.000 claims abstract description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- 239000003960 organic solvent Substances 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 9
- 239000008055 phosphate buffer solution Substances 0.000 claims description 8
- 239000007921 spray Substances 0.000 claims description 8
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 7
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 7
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 7
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 7
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- 238000004587 chromatography analysis Methods 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 239000007789 gas Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 238000001323 two-dimensional chromatography Methods 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical group COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- 239000008363 phosphate buffer Substances 0.000 claims description 3
- 239000012535 impurity Substances 0.000 abstract description 21
- 229920000642 polymer Polymers 0.000 abstract description 8
- 238000002347 injection Methods 0.000 abstract description 7
- 239000007924 injection Substances 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 7
- 238000004451 qualitative analysis Methods 0.000 abstract description 6
- 238000004780 2D liquid chromatography Methods 0.000 abstract description 4
- 238000012790 confirmation Methods 0.000 abstract description 2
- 238000011835 investigation Methods 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- SCHWIVHZZMAMTP-NCVGIQEBSA-N (6r,7r)-3-[[[4-[(z)-c-[[(6r,7r)-3-(acetyloxymethyl)-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]carbamoyl]-n-methoxycarbonimidoyl]-1,3-thiazol-2-yl]amino]methyl]-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1- Chemical compound N([C@@H]1C(N2C(=C(CNC=3SC=C(N=3)C(=N\OC)\C(=O)N[C@@H]3C(N4C(=C(COC(C)=O)CS[C@@H]43)C(O)=O)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 SCHWIVHZZMAMTP-NCVGIQEBSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 238000011993 High Performance Size Exclusion Chromatography Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003781 beta lactamase inhibitor Substances 0.000 description 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- VYVRIXWNTVOIRD-LRHBOZQDSA-N ciguatoxin CTX1B Chemical compound C([C@@]12[C@@H](C)[C@@H]([C@@H]3[C@H]([C@H]([C@H](C)[C@H]4O[C@H]5C[C@@H](C)C[C@H]6O[C@@]7(C)[C@H](O)C[C@H]8O[C@H]9C=C[C@H]%10O[C@H]%11C[C@@H]%12[C@H]([C@@H]([C@H]%13O[C@H](C=CC[C@@H]%13O%12)\C=C\[C@H](O)CO)O)O[C@@H]%11C=C[C@@H]%10O[C@@H]9C\C=C/C[C@@H]8O[C@@H]7C[C@@H]6O[C@@H]5C[C@@H]4O3)O)O2)C)[C@H](O)CO1 VYVRIXWNTVOIRD-LRHBOZQDSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
本发明属于药物分析技术领域,涉及一种定量及定性检测头孢噻肟钠他唑巴坦钠中有关物质的二维液相色谱‑串联质谱分析方法。该方法采用二维液相色谱和质谱方法联用,不仅能够有效地分离测定注射用头孢噻肟钠他唑巴坦钠复方中的有关杂质,还可以一并检测聚合物杂质。另外,该方法采用二维液相色谱和质谱方法联用,可以对头孢噻肟钠他唑巴坦钠中出现的主要杂质峰进行杂质类型的定性分析,使杂质结构的确证更为快捷,为制剂稳定性考察过程中有关物质的定性分析提供了一种切实有效的方法。
Description
技术领域
本发明涉及检测方法领域,具体涉及一种定量及定性检测头孢噻肟钠他唑巴坦钠中有关物质的二维液相色谱-串联质谱分析方法。
背景技术
注射用头孢噻肟钠他唑巴坦钠为头孢噻肟钠(Cefotaxime Sodium,CTX)和他唑巴坦钠(Tazobactam Sodium,TAZ)的复方制剂。头孢噻肟钠为第三代半合成头孢菌素,他唑巴坦钠为半合成β-内酰胺酶抑制剂,二者联合用药可以增强抑菌效果并拓宽抗菌谱。
在该复方制剂的杂质谱研究过程中,研究者发现有关杂质的类型及含量将直接影响制剂的质量和性能,因此需要合适的方法来检测复方制剂的有关物质。现有中国药典中头孢噻肟钠聚合物检测方法为凝胶色谱法,耗时较长,方法检测结果也不准确,难以达到质量控制的目的。而且现有质量标准中有关杂质除了对有关杂质检测以外,无法一并将聚合物杂质检测出来。故急需建立一种合适的方法来检测复方制剂中的有关物质(包括聚合物杂质),达到耗时短、检测结果准确、有效实现质量控制的目的。
发明内容
为了解决上述技术问题,本发明采用二维液相色谱和质谱方法联用,不仅能够有效地分离测定注射用头孢噻肟钠他唑巴坦钠复方中的有关杂质,还可以一并检测聚合物杂质。另外,本发明采用二维液相色谱和质谱方法联用,可以对头孢噻肟钠他唑巴坦钠中出现的主要杂质峰进行杂质类型的定性分析,使杂质结构的确证更为快捷,为制剂稳定性考察过程中有关物质的定性分析提供了一种切实有效的方法。
本发明提供一种定量及定性检测头孢噻肟钠他唑巴坦钠中有关物质的二维液相色谱-串联质谱分析方法,所述分析方法采用二维液相色谱-串联质谱法,所述分析方法包括下列步骤:
1)一维色谱:
流动相包括磷酸盐缓冲液和有机溶剂,其中所述磷酸盐缓冲液包括磷酸二氢钠和磷酸氢二钠,所述磷酸二氢钠和所述磷酸氢二钠分别为0.001-0.1mol/L,所述有机溶剂选自甲醇、乙醇、乙腈、异丙醇中的一种或多种,所述磷酸盐缓冲液与有机溶剂的比例为80-90:10-20;
2)二维色谱:
流动相包括流动相A和流动相B,其中所述流动相A选自甲醇、乙醇、乙腈、异丙醇中的一种或多种,所述流动相B为甲酸溶液;
4)二维质谱。
在一个实施方案中,所述分析方法包括下列步骤:
1)一维色谱:
磷酸盐缓冲液由磷酸二氢钠和磷酸氢二钠组成,有机溶剂选自甲醇、乙醇、乙腈、异丙醇、四氢呋喃、DMF中的一种或多种;
2)二维色谱:
洗脱梯度设置如下:
时间(min) | 流动相A(%) | 流动相B(%) |
0 | 0-10 | 90-100 |
12-22 | 0-10 | 90-100 |
23-33 | 90-100 | 0-10 |
27-37 | 90-100 | 0-10 |
28-38 | 0-10 | 90-100 |
和/或
3)二维质谱:
喷雾电压:1-10KV;金属毛细管温度:200-400℃。
在一个实施方案中,步骤1)中所用的色谱柱为TSKgel G2000SWxl(300×7.8mm,5μm)。
在一个实施方案中,步骤1)中所述磷酸盐缓冲液的pH值为6.5-7.5。
在一个实施方案中,步骤1)中所述有机溶剂为乙腈。
在一个实施方案中,步骤1)中流速为0.8mL/min,检测波长为254nm,柱温为30℃,进样量为10μL。
在一个实施方案中,步骤2)中所用的色谱柱为Welch,Ultimate Aq-C18(100×2.1mm,5μm)。
在一个实施方案中,步骤2)中的洗脱梯度为:
在一个实施方案中,步骤2)中检测波长为254nm,柱温为35℃,流速为0.3mL/min,进样量为20μL。
在一个实施方案中,步骤3)中,模式为ESI+,喷雾电压为3.8KV,金属毛细管温度为320℃,鞘气压力为30bar,辅助气压力为10bar,喷雾温度为150℃。
附图说明
图1为一维色谱条件下的供试品色谱图。
具体实施方案
实施例1柱切换二维液质分析
在一维色谱条件下,对各色谱峰进行截取,后经阀切换,在二维色谱条件下进行液质分析,对一维色谱检出杂质进行定性分析。
一维色谱条件:
色谱柱TSK gel G2000SWxl(填料:球状亲水改性硅胶;7.8mm×300mm,5μm);流动相:0.01mol/L磷酸盐缓冲液[0.01mol/L磷酸氢二钠溶液-0.01mol/L磷酸二氢钠溶液(61:39),用0.1mol/L磷酸调节pH值至7.0]-乙腈(85:15);流速:0.8mL/min;检测波长为254nm;柱温:30℃;进样量:10μL;稀释溶剂:流动相;样品浓度:1.0mg/ml(以头孢噻肟计)。用于HPSEC法分析聚合物杂质。
二维色谱条件:
流动相A:乙腈;
流动相B:0.1%甲酸溶液;
色谱柱:Welch,Ultimate Aq-C18(2.1mm×100mm,5μm);
检测波长:254nm;
柱温:35℃;
流速:0.3mL/min;
进样量:20μL;
梯度洗脱条件如表1所示。
表1
时间(分钟) | 流动相A(%) | 流动相B(%) |
0 | 1 | 99 |
17 | 1 | 99 |
28 | 100 | 0 |
32 | 100 | 0 |
33 | 1 | 99 |
质谱条件:QE Orbitrap Focus;模式:ESI+;喷雾电压:3.8KV;金属毛细管温度:320℃;鞘气压力:30bar;辅助气压力10bar;喷雾温度:150℃;S-lens RF level:55;二级碰撞能量:nce 10 20 40。
采用柱切换二维液质分析对注射用头孢噻肟钠他唑巴坦钠长期24个月稳定性考察样品进行有关物质检查,一维色谱条件下图谱如图1所示,对主峰前后共4个杂质峰在二维质谱条件下进行分析,二维质谱解析结果如表2所示。
表2
由此可见,采用柱切换二维液质分析方法,本品主要聚合物头孢噻肟杂质F在有关物质中能被检出,且与其它杂质完全分离,表明可以采用柱切换二维液质分析方法对本品有关物质及聚合物杂质进行定量及定性分析。
应当说明的是,以上所述仅为本发明的较佳实施例而已,并不用于限制本发明的范围,凡在本发明的精神和原则之内所作出的任何修改、等同的替换和改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种定量及定性检测头孢噻肟钠他唑巴坦钠中有关物质的二维液相色谱-串联质谱分析方法,其特征在于,所述分析方法包括下列步骤:
1)一维色谱:
流动相包括磷酸盐缓冲液和有机溶剂,其中所述磷酸盐缓冲液包括磷酸二氢钠和磷酸氢二钠,所述磷酸二氢钠和所述磷酸氢二钠分别为0.001-0.1mol/L,所述有机溶剂选自甲醇、乙醇、乙腈、异丙醇中的一种或多种,所述磷酸盐缓冲液与有机溶剂的比例为80-90:10-20;
2)二维色谱:
流动相包括流动相A和流动相B,其中所述流动相A选自甲醇、乙醇、乙腈、异丙醇中的一种或多种,所述流动相B为甲酸溶液;
3)二维质谱。
2.根据权利要求1所述的分析方法,其特征在于,
1)一维色谱:
磷酸盐缓冲液由磷酸二氢钠和磷酸氢二钠组成,有机溶剂选自甲醇、乙醇、乙腈、异丙醇中的一种或多种;
2)二维色谱:
洗脱梯度设置如下:
和/或
3)二维质谱:
喷雾电压:1-10KV;金属毛细管温度:200-400℃。
3.根据权利要求1-2中任一项所述的分析方法,其特征在于,步骤1)中所用的色谱柱为TSKgel G2000SWxl(300×7.8mm,5μm)。
4.根据权利要求1-3中任一项所述的分析方法,其特征在于,步骤1)中所述磷酸盐缓冲液的pH值为6.5-7.5。
5.根据权利要求1-4中任一项所述的分析方法,其特征在于,步骤1)中所述有机溶剂为乙腈。
6.根据权利要求1-5中任一项所述的分析方法,其特征在于,步骤1)中流速为0.8mL/min,检测波长为254nm,柱温为30℃,进样量为10μL。
7.根据权利要求1-6中任一项所述的分析方法,其特征在于,步骤2)中所用的色谱柱为Welch,Ultimate Aq-C18(100×2.1mm,5μm)。
8.根据权利要求1-7中任一项所述的分析方法,其特征在于,步骤2)中的洗脱梯度为:
9.根据权利要求1-8中任一项所述的分析方法,其特征在于,步骤2)中检测波长为254nm,柱温为35℃,流速为0.3mL/min,进样量为20μL。
10.根据权利要求1-9中任一项所述的分析方法,其特征在于,步骤3)中,模式为ESI+,喷雾电压为3.8KV,金属毛细管温度为320℃,鞘气压力为30bar,辅助气压力为10bar,喷雾温度为150℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210341487.4A CN116930390A (zh) | 2022-04-02 | 2022-04-02 | 一种检测头孢噻肟钠他唑巴坦钠中有关物质的二维液相色谱-串联质谱分析方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210341487.4A CN116930390A (zh) | 2022-04-02 | 2022-04-02 | 一种检测头孢噻肟钠他唑巴坦钠中有关物质的二维液相色谱-串联质谱分析方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116930390A true CN116930390A (zh) | 2023-10-24 |
Family
ID=88391115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210341487.4A Pending CN116930390A (zh) | 2022-04-02 | 2022-04-02 | 一种检测头孢噻肟钠他唑巴坦钠中有关物质的二维液相色谱-串联质谱分析方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116930390A (zh) |
-
2022
- 2022-04-02 CN CN202210341487.4A patent/CN116930390A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111175394B (zh) | 一种液相色谱串联质谱检测血浆儿茶酚胺及其代谢物的方法 | |
US11747349B2 (en) | Method for simultaneously detecting vitamin K1 and vitamin K2 in traces of blood | |
Qi et al. | Improving detection sensitivity of amino acids in thyroid tissues by using phthalic acid as a mobile phase additive in hydrophilic interaction chromatography-electrospray ionization-tandem mass spectrometry | |
van der Ham et al. | Quantification of metabolites in dried blood spots by direct infusion high resolution mass spectrometry | |
CN113049697A (zh) | 同时检测血液样本中醛固酮和肾素活性的方法及试剂盒 | |
WO2003089937A2 (en) | Quantitation of biological molecules | |
US11049703B2 (en) | Methods of evaluating performance of an atmospheric pressure ionization system | |
US20220003726A1 (en) | Method for matrix effect correction in quantitative mass spectrometric analysis of analytes in complex matrices | |
CN112730706A (zh) | 一种液相色谱串联质谱检测生物小分子标志物的方法 | |
CN114460188A (zh) | 检测人血浆儿茶酚胺中间代谢物的试剂盒及测试方法 | |
CN114441665A (zh) | 一种儿茶酚胺及其代谢物的检测方法 | |
CN109613144B (zh) | 一种儿茶酚胺类激素的检测方法 | |
CN110865137A (zh) | 一种血浆中醛固酮检测方法及检测试剂盒 | |
CN113933421A (zh) | 基于lc-msms技术的茶酚胺及其代谢物定量分析的方法 | |
Adamowicz et al. | Simple approach for evaluation of matrix effect in the mass spectrometry of synthetic cannabinoids | |
CN113917007A (zh) | 检测人尿液儿茶酚胺及其中间代谢物的试剂盒及测试方法 | |
Dong et al. | Quantitative analysis of glycerol levels in human urine by liquid chromatography–tandem mass spectrometry | |
CN116930390A (zh) | 一种检测头孢噻肟钠他唑巴坦钠中有关物质的二维液相色谱-串联质谱分析方法 | |
CN109212042B (zh) | 一种采用液质联用法测定盐酸培唑帕尼基因毒性杂质的分析方法 | |
CN110907569A (zh) | 一种同时检测血液样品中4种蛋白结合尿毒症毒素的方法 | |
CN114813993A (zh) | 一种尿液中有机磷酸酯检测方法 | |
CN111983112A (zh) | 血清中tmao及其相关代谢物的检测方法 | |
CN114624362A (zh) | 一种检测血清中晚期糖基化终末产物的试剂盒及其应用 | |
CN113376280A (zh) | 一种同时检测尿液样本中94种氨基酸的方法 | |
Wu et al. | Rapid Simultaneous Determination of Four Ganoderic Acids in Ganoderma (Chinese Name: Lingzhi) by Direct Infusion–Multiple Reaction Monitoring Cubed |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |